Signum Biosciences
About Signum STM Platform Pipeline Partners Careers News & Events Investors
Learn more about our STM platform
 
 

In the Lab

 

In the News

 

Join Us

Interested in a job at Signum? Visit our job postings section for a listing of our open positions.
 
 
In collaboration with the University of Pennsylvania we are investigating the effects of GPMs on UVB-induced inflammation.
 

Signum has been awarded a $1.6 million SBIR Phase II grant by the NIAID to continue the development of its topical STM anti-inflammatory technology for the treatment of skin disease.

   
           
 
In collaboration with the University of Medicine and Dentistry of New Jersey, we are investigating the effects of PPM compounds on α-synuclein phosphorylation in mouse models of Parkinson’s Disease.
 

A review by Signum founder Dr. Jeffry Stock on the role of “Protein carboxyl methylation and the biochemistry of memory” will be the cover article in Biological Chemistry (Nov 2009).

   
           
 

Other News

   
 

May 2009

Signum presents 2 posters highlighting the efficacy in safety of GPMs at the 69th annual Society for Investigative Dermatology (SID) in Montreal. Read More


May 2009

Dr. Richard D. Granstein presents at the 69th annual Society of Investigative Dermatology that GPMs are effective in reducing key inflammatory mediators in a cell based that may be useful for the identification of potential new therapeutics for rosacea. Read More


March 2009

Dr. Zoe Draelos presents Signum’s GPM Technology as a new class of topical anti-inflamatories at the American Academy of Dermatology (AAD) meeting in San Francisco. Read More

   
 
 
Site map   |   Contact Us   |   Privacy Policy   |   Terms of Use   |   © Signum Biosciences, Inc., All Rights Reserved.